BBIO: BridgeBio Pharma, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-08-17 | Fell below 5% | KKR Genetic Disorder L.P. | 4.70% | SEC | |
| 2026-08-03 | 13G amendment | Farallon Capital Management, L.L.C. | 5.50% | SEC | |
| 2026-07-27 | Fell below 5% | BlackRock, Inc. | 4.96% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.